Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: A combination analysis study

Alessandro Capuano, Alice De Corato, Mariangela Treglia, Giuseppe Tringali, Cinzia Dello Russo, Pierluigi Navarra

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Combination of two or more analgesics is widely used for the treatment of moderate and severe pain syndromes, allowing usage of lower doses of each compound and thereby limiting side effects; there is currently a large interest in investigating the potential advantages of combinations between opioids and non-steroidal inflammatory drugs (NSAIDs), coxibs in particular. The rat orofacial formalin test is a useful pre-clinical model of inflammatory trigeminal pain for evaluating antinociceptive activity of analgesics and their combinations. Injection of formalin in the rat wiskerpad induces a stereotyped response (rubbing), consisting of two distinct phases: a first 'phasic' phase and a second 'tonic' phase. In this work we tested a partial agonist to μ-opioid receptors, buprenorphine, and a selective cyclo-oxygenase-2 inhibitor, lumiracoxib, each of which given i.p. either alone or in combination. Buprenorphine reduced nociception both in the first and in the second phase, whereas lumiracoxib induced antinociception in the second phase only. The interaction between the two drugs was assessed through isobolographic analysis after combined administration at a fixed dose ratio. Such combination produced a dose-dependent antinociceptive effect in both phases. We observed a statistical difference between the theoretical and the experimental ED50, which indicated synergistic interaction in the second phase. Concerning the first phase, we assumed that the antinociceptive effects were almost completely to be attributed to buprenorphine, since lumiracoxib was ineffective when administered alone. However, we found an unexpected difference between the theoretical and experimental ED50, suggesting synergism in the first phase as well.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalEuropean Journal of Pharmacology
Volume605
Issue number1-3
DOIs
Publication statusPublished - Mar 1 2009

Fingerprint

Buprenorphine
Pain Measurement
Analgesics
Pain
Nociception
Cyclooxygenase Inhibitors
Cyclooxygenase 2 Inhibitors
Opioid Receptors
Pharmaceutical Preparations
Opioid Analgesics
Formaldehyde
Injections
lumiracoxib
Therapeutics

Keywords

  • Buprenorphine
  • Formalin
  • Isobolographic analysis
  • Lumiracoxib
  • Rat orofacial test

ASJC Scopus subject areas

  • Pharmacology

Cite this

Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test : A combination analysis study. / Capuano, Alessandro; De Corato, Alice; Treglia, Mariangela; Tringali, Giuseppe; Dello Russo, Cinzia; Navarra, Pierluigi.

In: European Journal of Pharmacology, Vol. 605, No. 1-3, 01.03.2009, p. 57-62.

Research output: Contribution to journalArticle

Capuano, Alessandro ; De Corato, Alice ; Treglia, Mariangela ; Tringali, Giuseppe ; Dello Russo, Cinzia ; Navarra, Pierluigi. / Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test : A combination analysis study. In: European Journal of Pharmacology. 2009 ; Vol. 605, No. 1-3. pp. 57-62.
@article{e92d65bdf7454bcca0f59fd8f047f018,
title = "Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: A combination analysis study",
abstract = "Combination of two or more analgesics is widely used for the treatment of moderate and severe pain syndromes, allowing usage of lower doses of each compound and thereby limiting side effects; there is currently a large interest in investigating the potential advantages of combinations between opioids and non-steroidal inflammatory drugs (NSAIDs), coxibs in particular. The rat orofacial formalin test is a useful pre-clinical model of inflammatory trigeminal pain for evaluating antinociceptive activity of analgesics and their combinations. Injection of formalin in the rat wiskerpad induces a stereotyped response (rubbing), consisting of two distinct phases: a first 'phasic' phase and a second 'tonic' phase. In this work we tested a partial agonist to μ-opioid receptors, buprenorphine, and a selective cyclo-oxygenase-2 inhibitor, lumiracoxib, each of which given i.p. either alone or in combination. Buprenorphine reduced nociception both in the first and in the second phase, whereas lumiracoxib induced antinociception in the second phase only. The interaction between the two drugs was assessed through isobolographic analysis after combined administration at a fixed dose ratio. Such combination produced a dose-dependent antinociceptive effect in both phases. We observed a statistical difference between the theoretical and the experimental ED50, which indicated synergistic interaction in the second phase. Concerning the first phase, we assumed that the antinociceptive effects were almost completely to be attributed to buprenorphine, since lumiracoxib was ineffective when administered alone. However, we found an unexpected difference between the theoretical and experimental ED50, suggesting synergism in the first phase as well.",
keywords = "Buprenorphine, Formalin, Isobolographic analysis, Lumiracoxib, Rat orofacial test",
author = "Alessandro Capuano and {De Corato}, Alice and Mariangela Treglia and Giuseppe Tringali and {Dello Russo}, Cinzia and Pierluigi Navarra",
year = "2009",
month = "3",
day = "1",
doi = "10.1016/j.ejphar.2008.12.029",
language = "English",
volume = "605",
pages = "57--62",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test

T2 - A combination analysis study

AU - Capuano, Alessandro

AU - De Corato, Alice

AU - Treglia, Mariangela

AU - Tringali, Giuseppe

AU - Dello Russo, Cinzia

AU - Navarra, Pierluigi

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Combination of two or more analgesics is widely used for the treatment of moderate and severe pain syndromes, allowing usage of lower doses of each compound and thereby limiting side effects; there is currently a large interest in investigating the potential advantages of combinations between opioids and non-steroidal inflammatory drugs (NSAIDs), coxibs in particular. The rat orofacial formalin test is a useful pre-clinical model of inflammatory trigeminal pain for evaluating antinociceptive activity of analgesics and their combinations. Injection of formalin in the rat wiskerpad induces a stereotyped response (rubbing), consisting of two distinct phases: a first 'phasic' phase and a second 'tonic' phase. In this work we tested a partial agonist to μ-opioid receptors, buprenorphine, and a selective cyclo-oxygenase-2 inhibitor, lumiracoxib, each of which given i.p. either alone or in combination. Buprenorphine reduced nociception both in the first and in the second phase, whereas lumiracoxib induced antinociception in the second phase only. The interaction between the two drugs was assessed through isobolographic analysis after combined administration at a fixed dose ratio. Such combination produced a dose-dependent antinociceptive effect in both phases. We observed a statistical difference between the theoretical and the experimental ED50, which indicated synergistic interaction in the second phase. Concerning the first phase, we assumed that the antinociceptive effects were almost completely to be attributed to buprenorphine, since lumiracoxib was ineffective when administered alone. However, we found an unexpected difference between the theoretical and experimental ED50, suggesting synergism in the first phase as well.

AB - Combination of two or more analgesics is widely used for the treatment of moderate and severe pain syndromes, allowing usage of lower doses of each compound and thereby limiting side effects; there is currently a large interest in investigating the potential advantages of combinations between opioids and non-steroidal inflammatory drugs (NSAIDs), coxibs in particular. The rat orofacial formalin test is a useful pre-clinical model of inflammatory trigeminal pain for evaluating antinociceptive activity of analgesics and their combinations. Injection of formalin in the rat wiskerpad induces a stereotyped response (rubbing), consisting of two distinct phases: a first 'phasic' phase and a second 'tonic' phase. In this work we tested a partial agonist to μ-opioid receptors, buprenorphine, and a selective cyclo-oxygenase-2 inhibitor, lumiracoxib, each of which given i.p. either alone or in combination. Buprenorphine reduced nociception both in the first and in the second phase, whereas lumiracoxib induced antinociception in the second phase only. The interaction between the two drugs was assessed through isobolographic analysis after combined administration at a fixed dose ratio. Such combination produced a dose-dependent antinociceptive effect in both phases. We observed a statistical difference between the theoretical and the experimental ED50, which indicated synergistic interaction in the second phase. Concerning the first phase, we assumed that the antinociceptive effects were almost completely to be attributed to buprenorphine, since lumiracoxib was ineffective when administered alone. However, we found an unexpected difference between the theoretical and experimental ED50, suggesting synergism in the first phase as well.

KW - Buprenorphine

KW - Formalin

KW - Isobolographic analysis

KW - Lumiracoxib

KW - Rat orofacial test

UR - http://www.scopus.com/inward/record.url?scp=60349083541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60349083541&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.12.029

DO - 10.1016/j.ejphar.2008.12.029

M3 - Article

C2 - 19168053

AN - SCOPUS:60349083541

VL - 605

SP - 57

EP - 62

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -